Concise Communication
Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide
Sarah J. Bingham MA, MB, BChir, MRCP,
Maya H. Buch MB, ChB, MRCP, Michael A. Kerr BSc, PhD, FRCPath,
Paul Emery MA, MB, BChir, MD, FRCP,
Anabela Tavares Valadäo Barcelos MD,
Sarah J. Bingham MA, MB, BChir, MRCP
Leeds General Infirmary, Leeds, UK
Search for more papers by this authorMichael A. Kerr BSc, PhD, FRCPath
Leeds General Infirmary, Leeds, UK
Search for more papers by this authorPaul Emery MA, MB, BChir, MD, FRCP
Leeds General Infirmary, Leeds, UK
Search for more papers by this authorAnabela Tavares Valadäo Barcelos MD
University Hospital of Coimbra Coimbra, Portugal
Search for more papers by this authorSarah J. Bingham MA, MB, BChir, MRCP,
Maya H. Buch MB, ChB, MRCP, Michael A. Kerr BSc, PhD, FRCPath,
Paul Emery MA, MB, BChir, MD, FRCP,
Anabela Tavares Valadäo Barcelos MD,
Sarah J. Bingham MA, MB, BChir, MRCP
Leeds General Infirmary, Leeds, UK
Search for more papers by this authorMichael A. Kerr BSc, PhD, FRCPath
Leeds General Infirmary, Leeds, UK
Search for more papers by this authorPaul Emery MA, MB, BChir, MD, FRCP
Leeds General Infirmary, Leeds, UK
Search for more papers by this authorAnabela Tavares Valadäo Barcelos MD
University Hospital of Coimbra Coimbra, Portugal
Search for more papers by this author
References
- 1 Gunnarsson I, Nordmark B, HassanBakri A, Grondal G, Larsson P, Forslid J, et al. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment—the role of IL-10 and HLA Rheumatology (Oxford) 2000; 39: 886–93.
- 2 Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383–90.
- 3 Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti–tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552–63.
- 4 Kiely PD, Johnson DM. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology (Oxford) 2002; 41: 631–7.
- 5 Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35.
- 6 Jarrett SJ, Cunnane G, Conaghan P, Bingham SJ, Buch MH, Quinn MA, et al. Anti-tumour necrosis factor-α therapy induced vasculitis: case series. J Rheumatol 2003; 30: 2287–91.
- 7 Lipsky PE, van der Heijde DM, StClair EW, Furst DE, Breedveld FC, Kalden JR, et al, the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602.
- 8 De Rycke L, Kruithof E, van Damme N, Hoffman IE, van den Bossche N, Van den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003; 48: 1015–23.
